Floatz logo

TENOFOVIR DISOPROXIL FUMARATE

Carcinoma, Hepatocellular

Sun Yat-sen UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

521 Active assets in the Carcinoma, Hepatocellular cohort.

Asset / SponsorPhaseRating
Huaier Granule
Tongji Hospital
Phase 4BBB
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

TENOFOVIR DISOPROXIL FUMARATE is also rated in:

chronic hepatitis B virus infectionDormant
BBB
Indicative ·
72 / 100
View asset →
HIV infectious diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
lipodystrophyDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →